You're about to read something we haven't shown anyone else.

A complete business plan, regulatory posture, and technical architecture for a multi-tenant telehealth + compounding-pharmacy platform. Years of decisions condensed into one read.

Before we share it: a binding NDA and a narrowly-scoped non-compete. We make the page beautiful so you'll want to read every word; we make the legal real so you can't use it to build a copy.

What you're agreeing to, briefly.

i.5-year confidentiality on everything you see beyond this page.
ii.24-month non-compete specifically against building a competing multi-tenant telehealth-pharmacy platform, see scope below.
iii.24-month non-solicitation of staff, tenants, pharmacy partners, providers, and vendors.
iv.Your name, email, IP, and user agent are recorded with the signature.
v.Every view, scroll, and attempt to copy / screenshot / open DevTools is logged against your signed identity.

Scope of the non-compete · read carefully

The covenant restricts one thing.

Building a competing multi-tenant telehealth-pharmacy platform business, a SaaS or PaaS that sells the technology layer to other brand owners (a "Shopify of telehealth"-style platform).

Restricted

-Multi-tenant telehealth platform serving 2+ unaffiliated brands
-White-label 'build your own Hims' platform
-Multi-tenant Rx authoring + NCPDP transmission infrastructure sold to brand owners
-Shared provider marketplace across multiple unaffiliated brands

Expressly allowed

+Operating your own single-brand DTC telehealth company
+Running a stand-alone pharmacy (retail, 503A, 503B, mail-order)
+Working as a clinician / pharmacist / provider
+Single-condition virtual clinics
+Internal-use telehealth tech for one business
+Non-telehealth multi-tenant SaaS in any unrelated vertical

In short: you can compete with our consumer brands; you can run a pharmacy; you can work in healthcare. You just can't build another platform that sells the same technology layer to other brand owners.

One page · two signatures · then the gate

Full legal name

Mobile phone · for SMS verification

US mobile only. We'll text a 6-digit verification code to this number at the next step.

Company · optional

Your role · optional

Read both documents in full. The checkbox stays disabled until you've scrolled through.

Mutual Confidentiality + Non-Disclosure

v 2026-05-28-v1

Scroll to read

MUTUAL CONFIDENTIALITY + NON-DISCLOSURE AGREEMENT (NDA)

Effective on the date the Recipient (defined below) signs this Agreement by submitting the form below.

PARTIES.
1. Amino Club LLC and Affiliates ("Disclosing Party").
2. The undersigned individual, signing in their personal capacity AND on behalf of any entity they represent ("Recipient").

PURPOSE.
The Disclosing Party intends to share with the Recipient confidential information about a multi-tenant telehealth + compounding-pharmacy platform, including its business model, technical architecture, regulatory posture, pricing, partnerships, brand strategy, and roadmap (collectively, the "Confidential Information"). The Recipient wishes to receive that information for the purpose of evaluation only (the "Purpose").

CONFIDENTIAL INFORMATION DEFINED.
Confidential Information includes, without limitation, every section of the disclosure page that follows this Agreement, all diagrams and charts displayed thereon, all decisions documented therein, all vendor relationships described, all financial information, all source code references, all roadmap items, and all derivative materials (notes, summaries, screenshots, transcriptions). It includes information disclosed orally, in writing, visually, or in any other form.

RECIPIENT'S OBLIGATIONS. Recipient shall:
(a) Hold all Confidential Information in strict confidence using at least the same degree of care Recipient uses to protect Recipient's own confidential information, but in no event less than reasonable care;
(b) Not use Confidential Information for any purpose other than the Purpose;
(c) Not disclose, publish, copy, reproduce, transmit, share, or distribute any Confidential Information to any third party, including AI services, social networks, journalists, investors, employers, competitors, or family members, without the Disclosing Party's prior written consent (an email from an authorized signatory of the Disclosing Party suffices);
(d) Not screenshot, photograph, transcribe, summarize for external sharing, or otherwise copy the disclosure page or any portion of it;
(e) Not reverse-engineer, derive, or infer technical implementations beyond what is expressly displayed;
(f) Promptly notify the Disclosing Party in writing if Recipient becomes aware of any actual or threatened unauthorized disclosure or use;
(g) Upon written request from the Disclosing Party, certify in writing that Recipient has ceased all use of Confidential Information and destroyed any copies in Recipient's possession.

EXCLUSIONS. Confidential Information does not include information that Recipient can prove with contemporaneous written records was:
(a) Already in Recipient's possession prior to receipt from the Disclosing Party, without obligation of confidentiality;
(b) Publicly known through no breach of this Agreement;
(c) Independently developed by Recipient without use of or reference to Confidential Information; or
(d) Disclosed to Recipient by a third party with the legal right to do so and without obligation of confidentiality.

COMPELLED DISCLOSURE. If Recipient is legally compelled to disclose Confidential Information (e.g., by subpoena or court order), Recipient shall give the Disclosing Party prompt written notice and reasonable opportunity to seek a protective order before disclosing.

NO LICENSE. Nothing in this Agreement grants Recipient any license to, or ownership interest in, any Confidential Information, intellectual property, trademark, or business of the Disclosing Party. All Confidential Information remains the sole property of the Disclosing Party.

TERM. This Agreement is effective on the date of signature and continues for five (5) years thereafter. Recipient's confidentiality obligations survive any termination of this Agreement and continue in perpetuity for any information that meets the legal definition of a "trade secret" under applicable law.

REMEDIES. Recipient acknowledges that any breach of this Agreement would cause irreparable harm to the Disclosing Party for which monetary damages would be inadequate. Accordingly, the Disclosing Party is entitled to seek injunctive relief, specific performance, and any other equitable relief, in addition to monetary damages, attorneys' fees, and costs. Recipient waives any requirement for the Disclosing Party to post bond in seeking such relief.

GOVERNING LAW. This Agreement is governed by the laws of the State of Delaware (without regard to its conflict-of-laws principles). The parties consent to the exclusive jurisdiction of state and federal courts located in Delaware for any dispute arising from this Agreement.

NO WAIVER. No failure or delay by the Disclosing Party in exercising any right under this Agreement constitutes a waiver of that right.

SEVERABILITY. If any provision of this Agreement is held unenforceable, the remaining provisions remain in full force.

ELECTRONIC SIGNATURE. Recipient acknowledges that submission of the form below, with Recipient's typed full legal name as their electronic signature, constitutes a legally binding signature equivalent to a wet-ink signature under the U.S. Electronic Signatures in Global and National Commerce Act (E-SIGN, 15 U.S.C. § 7001 et seq.) and applicable state law.

ENTIRE AGREEMENT. This Agreement, together with the Non-Compete Covenant signed concurrently, constitutes the entire agreement between the parties with respect to its subject matter and supersedes any prior agreements.

BY SIGNING BELOW, I acknowledge that I have read this Agreement in full, understood it, and agreed to be bound by its terms.

I have read the NDA in full and agree to be bound by its terms.

Non-Compete and Non-Solicitation Covenant

v 2026-05-28-v2

Scroll to read

NON-COMPETE AND NON-SOLICITATION COVENANT

Effective on the date the Recipient (defined below) signs by submitting the form below.

PARTIES. Same as the Mutual Confidentiality Agreement signed concurrently, Amino Club LLC and Affiliates ("Disclosing Party") and the undersigned individual ("Recipient").

ACKNOWLEDGMENT. Recipient acknowledges that the Disclosing Party will share with Recipient material non-public information about a unique multi-tenant telehealth + dispensing-pharmacy platform business (the "Restricted Business") that the Disclosing Party has invested substantial time, resources, and trade secrets to develop. Recipient acknowledges that this information would give an unfair competitive advantage to anyone who used it to build a competing platform business.

DEFINED SCOPE OF THE RESTRICTED BUSINESS. For purposes of this Covenant, the "Restricted Business" means: a software platform, software-as-a-service ("SaaS"), platform-as-a-service ("PaaS"), or other multi-tenant technology offering that enables two or more unaffiliated commercial brands to operate prescription-grade telehealth and dispensing-pharmacy storefronts on shared technical infrastructure. The defining characteristic of the Restricted Business is its multi-tenancy: it sells the technology layer to other brand owners, rather than sells medications, consultations, or care to end patients. Without limiting the foregoing, the Restricted Business includes any offering whose feature set materially overlaps with the disclosure page in any combination of the following: per-tenant branding/theming infrastructure, multi-tenant clinical-intake / protocol authoring, multi-tenant electronic medical record, shared or routed provider marketplace across multiple unaffiliated tenants, shared or routed pharmacy fulfillment across multiple unaffiliated tenants, multi-tenant commerce + pricing + catalog configuration, multi-tenant audit + compliance infrastructure, multi-tenant prescription authoring / NCPDP transmission, multi-tenant payment + payout orchestration, and multi-tenant developer APIs targeted at telehealth-pharmacy brand owners.

EXPRESSLY OUTSIDE THE RESTRICTED BUSINESS (PERMITTED ACTIVITY). For the avoidance of doubt, and notwithstanding anything to the contrary above, the Restricted Business does NOT include, and Recipient is NOT restricted from, any of the following:

(i) Operating, owning, advising, financing, or working at a single-brand direct-to-consumer telehealth company (including but not limited to brands of any size targeting consumers directly with their own clinical care, regardless of compounded or non-compounded products);
(ii) Operating, owning, advising, financing, or working at a stand-alone pharmacy (retail, mail-order, 503A, or 503B), so long as that pharmacy does not provide multi-tenant platform infrastructure to two or more unaffiliated telehealth-pharmacy brand owners;
(iii) Operating, owning, advising, financing, or working at a single-tenant clinical practice or provider network;
(iv) Operating, owning, advising, financing, or working at a vertical-specific telehealth offering that does not provide a generalized multi-tenant platform to other brand owners (e.g., a single-condition virtual clinic);
(v) Working as a clinician, pharmacist, lawyer, accountant, or other licensed professional providing services directly to patients or businesses, in a capacity that does not involve building or selling competing multi-tenant platform infrastructure;
(vi) Building, advising, or operating internal-use technology for a single business that is not licensed or made available to third-party brand owners;
(vii) Building or operating a non-telehealth multi-tenant SaaS / PaaS business (e.g., e-commerce for non-Rx goods, payments infrastructure, marketplaces in unrelated verticals);
(viii) General-purpose tooling (developer libraries, frameworks, AI tools, etc.) that is not marketed to or designed for multi-tenant telehealth-pharmacy brand operators specifically.

The intent of this carve-out is precise: the Disclosing Party's protectable interest is the Restricted Business as defined above. It is not intended to chill, restrict, or prevent the Recipient from competing with the Disclosing Party's own first-party consumer brands, from running a pharmacy, or from working in healthcare generally, only from building or assisting another company in building a directly substitutable multi-tenant platform.

NON-COMPETE COVENANT. For a period of twenty-four (24) months from the date of signature, Recipient shall NOT, directly or indirectly, whether as principal, agent, employee, employer, consultant, partner, shareholder (other than passive ownership of less than 1% of a publicly traded company), advisor, or financier:

(a) Develop, launch, operate, license, sell, finance, or materially advise any business that falls within the Restricted Business as defined above;
(b) Use any Confidential Information (as defined in the concurrently signed Confidentiality Agreement) to inform any business activity outside of evaluating a potential relationship with the Disclosing Party.

NON-SOLICITATION. For the same twenty-four (24) month period, Recipient shall NOT, directly or indirectly:

(c) Solicit, hire, or attempt to hire any employee, contractor, partner, vendor, or advisor of the Disclosing Party with whom Recipient came into contact through the Confidential Information;
(d) Solicit, divert, or attempt to divert any tenant customer, pharmacy partner, provider, or vendor of the Disclosing Party with whom Recipient came into contact through the Confidential Information, for the purpose of providing services within the Restricted Business.

GEOGRAPHIC SCOPE. This covenant applies in any geography where the Disclosing Party operates or has documented plans to operate during the covenant period, including the United States and any international markets identified in the disclosure page.

REASONABLENESS. Recipient acknowledges that the duration, geographic scope, and substantive scope of this covenant, and in particular the narrow definition of the Restricted Business plus the express carve-outs above, are reasonable and necessary to protect the Disclosing Party's legitimate business interests in the platform business without unduly restraining the Recipient's general right to work in healthcare. Recipient further acknowledges that Recipient has been given a meaningful opportunity to evaluate this covenant prior to signing.

SEVERABILITY. If any court of competent jurisdiction determines any portion of this covenant to be unenforceable, the parties intend that the court reform the covenant to the maximum extent enforceable in that jurisdiction.

REMEDIES. Same as the concurrently signed Confidentiality Agreement.

GOVERNING LAW + JURISDICTION. Same as the concurrently signed Confidentiality Agreement.

JURISDICTIONAL NOTICE. Recipient acknowledges that this covenant may be unenforceable in jurisdictions that prohibit non-compete agreements (including California for most employment relationships, and other states as applicable). In such jurisdictions, Recipient agrees that the non-solicitation portions ((c) and (d) above) shall remain enforceable to the maximum extent permitted by law, even if the non-competition portions ((a) and (b)) are reduced.

ELECTRONIC SIGNATURE. Same E-SIGN Act and state-law equivalence as the concurrently signed Confidentiality Agreement.

BY SIGNING BELOW, I acknowledge that I have read this Covenant in full, understood the scope of the Restricted Business and the express carve-outs above, and agreed to be bound by its terms.

I have read the Non-Compete Covenant in full and agree to be bound by its terms.

Signature · type your full legal name

Your typed name + IP address + timestamp will be recorded as your binding signature under the U.S. E-SIGN Act and state-law equivalents.

Records: your name, email, IP address, user agent, geographic region, and the exact NDA + Non-Compete versions you signed. Retained 7 years per platform compliance policy.

This is a draft template. Disclosing Party may modify the language at any time before signature. Once signed, your signature is bound to the version shown above.